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Abstract: Mucoadhesive drug therapy destined for localized drug treatment is gaining 
increasing importance in today’s drug development. Chitosan, due to its known 
biodegradability, bioadhesiveness and excellent safety profile offers means to improve 
mucosal drug therapy. We have used chitosan as mucoadhesive polymer to develop 
liposomes able to ensure prolonged residence time at vaginal site. Two types of 
mucoadhesive liposomes, namely the chitosan-coated liposomes and chitosan-containing 
liposomes, where chitosan is both embedded and surface-available, were made of soy 
phosphatidylcholine with entrapped fluorescence markers of two molecular weights,  
FITC-dextran 4000 and 20,000, respectively. Both liposomal types were characterized for 
their size distribution, zeta potential, entrapment efficiency and the in vitro release profile, 
and compared to plain liposomes. The proof of chitosan being both surface-available as  
well as embedded into the liposomes in the chitosan-containing liposomes was found. The 
capability of the surface-available chitosan to interact with the model porcine mucin was 
confirmed for both chitosan-containing and chitosan-coated liposomes implying potential 
mucoadhesive behavior. Chitosan-containing liposomes were shown to be superior in 
respect to the simplicity of preparation, FITC-dextran load, mucoadhesiveness and in vitro 
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release and are expected to ensure prolonged residence time on the vaginal mucosa 
providing localized sustained release of entrapped model substances. 
Keywords: chitosan; drug delivery; mucoadhesion; vaginal therapy; FITC-dextran 
 
1. Introduction 
Chitosan is a linear polysaccharide that is composed of copolymers of β(1-4)-linked  
N-acetylglucosamide and glucosamine. It is obtained by deacetylation of chitin, a natural polymer 
obtained from various sources, such as crustacean shells, fungi and bacteria; as a pharmaceutical raw 
material it is mostly obtained as a waste product of the shell fish industry, and is interesting as an 
affordable, renewable and sustainable product [1–4]. Chitosan can be obtained exhibiting various 
degrees of deacetylation (DD) and molecular weights, which determine its physicochemical and 
biological properties. The DD, as well as molecular weight, are directly proportional to physical 
properties, such as the solubility and viscosity. The mucoadhesiveness, antimicrobial effects and other 
biological properties are also related to the DD [5]. Although chitosan exhibits toxic effects on several 
bacteria, fungi and parasites, it is regarded safe for use in humans [6]. Chitosan is biodegradable and 
has been proven to be a safe and non-toxic excipient in pharmaceutical formulations such as a dressing 
in wound healing, in tissue engineering, and for surface modification of implantable devices [2,7,8]. In 
addition, it can be easily manufactured into nanofiber, beads, micro- and nanoparticles, among other 
delivery systems [9]. 
Chitosan can be used as mucoadhesive polymer for drug delivery via various mucosal surfaces.  
The positive charge of chitosan molecule is considered to be the main factor responsible for its 
mucoadhesive properties; the electrostatic interactions between the mucus layer containing negatively 
charged mucin and positively charged chitosan are considered the reason for its good adhesion on the 
mucosal surfaces [10]. In addition to the electrostatic forces there are other possible contributing 
factors to its mucoadhesivness, such as its wettability, entanglement, possible interactions with the 
mucin from the weaker Van der Waal’s forces, and hydrogen bonding, as well as the hydrophobic 
interactions between the hydrophobic segments of the molecules. This enhanced bioadhesiveness will 
lead to increased retention time at the administration site, ensuring localized drug release and improved 
therapy. The use of chitosan in drug delivery systems has been extensive, both for systemic and 
localized drug delivery [4,11]; it has been shown to be a valuable excipient in tablets, emulsions, 
powders and gels providing a controlled release of the incorporated drug. On the smaller end of the 
scale chitosan has also been used in the development of chitosan-based nanoparticles, nanoemulsions 
and as a coating material for liposomes [12–18]. 
Local treatment with mucoadhesive drug delivery systems can offer several advantages, such as 
reduced administration frequencies, prolonged residence time and avoidance of disadvantages of 
systemic treatment. Additional advantage of chitosan as a mucoadhesive polymer is that it does not 
inactivate upon contact with mucin and its mucoadhesiveness does not weaken with time [19]. 
In respect to vaginal drug delivery systems, the main obstacles that need to be overcome for 
successful localized therapy are the great variations in the local pH and epithelial thickness depending 
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on the age and hormone status, and a highly folded epithelial surface. Nanomedicine, particularly 
mucoadhesive nanopharmaceuticals, offers means of achieving a uniform distribution throughout the 
vaginal site [16,20]. Our group has been extensively studying the delivery systems able to improve 
local vaginal drug therapy. The mucoadhesiveness of chitosan is pH-dependent and stronger at the 
acidic pH providing an additional reason why we believe that chitosan has a great potential in vaginal 
delivery. We have recently developed several chitosan-based mucoadhesive drug delivery systems for 
local vaginal treatment [17,21,22]. The methods used to include/attach chitosan to the delivery systems 
varied from a simple one-pot preparation method, where chitosan was included in the first preparation 
step [21], to chitosan coating of the surface of preformed liposomes [17] or chitosan used as an 
excipient in pre-liposome tablets [22]. 
In respect to simplicity of the manufacturing conditions, the one-pot preparation method for 
production of chitosan-containing liposomes is particularly interesting [21]. The preparation process 
resulted in an in situ coating of the liposomes where it was hypothesized that the polymer is found both 
as a coating on the surface of the chitosan-containing liposomes and embedded in the aqueous 
compartment within the liposomes. In this study we wanted to further characterize this novel delivery 
system, particularly focusing on the mucoadhesiveness of the system and its ability to incorporate 
larger drug molecules, like biologicals. For that purpose we prepared chitosan-containing liposomes 
with two different model substances (fluorescein isothiocyanate dextran of Mw 4000 and 20,000 Da,  
FITC-dextran 4 and FITC-dextran 20, respectively). The ability of this type of liposomes to interact  
with mucin and, at the same time, provide sustained release of entrapped fluorescent substances  
was compared with the non-mucoadhesive (plain) and chitosan-coated liposomes containing the  
same dextran. 
2. Results and Discussion 
In order to achieve optimal treatment in local vaginal drug delivery it is important to provide a 
sufficient amount of the drug at the vaginal site for a sufficient amount of time [23]. Moreover, lower 
doses, drug targeting to the vaginal site, lower administration frequency may also lead to cost 
reduction of the therapy [24]. The important features of a drug delivery system directly contributing to 
the efficacy of the therapy are the drug load (entrapment of the drug within the carrier) and the 
mucoadhesion of the system, which will both ensure the increased concentration of the drug at the 
active site and its prolonged residence time [20]. In addition, the mucoadhesive delivery system needs 
to exhibit a predictable release of the entrapped/incorporated drug and be of a size that allows the 
system to reach the target tissue within the vaginal cavity [25]. These important characteristics were 
therefore the focus of this study. 
2.1. Characterization of Liposomes 
The entrapment of the model substances in three types of liposomes is presented in Figure 1.  
Both the low and high molecular weight FITC-dextrans were entrapped to the highest extent within 
chitosan-containing liposomes. The entrapment within the chitosan-coated and plain liposomes was 
similar for each type of FITC-dextran, and the pattern was consistent for both the low and high 
molecular weight FITC-dextrans. This may be explained by the fact that the liposomes that are the 
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basis of the chitosan-coated liposomes are the same as the plain liposomes, except for the additional 
chitosan coating on their surface, and that the FITC-dextrans have been entrapped into the liposomes 
prior to the coating. The chitosan-containing liposomes are entirely different types of liposomes as 
they are formed in the presence of both chitosan and drug, in this case the model FITC-dextran. The 
presence of chitosan inside as well as outside the liposomes probably contributes to pulling more of the 
substance into the aqueous compartments of the liposomes. Both FITC-dextran and chitosan have a 
high number of hydrogen-bonding capable groups, which may contribute positively to pulling more 
FITC-dextrans into the liposomes; in addition, the chitosan embedded in the liposomal structure may 
disorganize the structure of the lipid bilayers and provide more room for the FITC-dextran inside the 
aqueous compartments of the chitosan-containing liposomes. As expected, the entrapment of  
FITC-dextran 20 was less than FITC-dextran 4 for all types of vesicles, which can be attributed to its 
larger molecular weight. However, both model substances were entrapped with rather high efficiencies 
indicating that the chitosan-containing liposomes can entrap sufficient amounts of larger molecules, 
such as biologicals, within their structure. 
 
Figure 1. Entrapment of two FITC-dextrans in chitosan-containing liposomes, chitosan-coated 
liposomes, and plain liposomes. All values represent the mean ± SD (n = 3). 
The liposomes prepared by the one-pot method are known to be larger than 1 micron with rather 
high polydispersity index (PI). They were also clearly of multilamellar nature [21]. To gain more 
control over the polydispersity of the samples, since this is expected to influence both the distribution 
of liposomes within vaginal cavity and the drug release rate, the sonication was applied. The sizes of 
the sonicated liposomes are best described by bimodal distributions where similarly sized liposomes 
are grouped in populations and the volume-weighted percentage of particles with a specific mean are 
calculated (Table 1). Chitosan-coated liposomes were the smallest of tested formulations, whereas the 
plain liposomes were the largest. Interestingly, liposomes containing FITC-dextran 20 were of smaller 
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sizes than the same liposomes containing FITC-dextran 4. The smaller size of the liposomes containing  
FITC-dextran 20 can also be seen as a contributing factor to why the larger model substance was 
entrapped to a lower extent as compared to the FITC-dextran 4; smaller liposomes have less available 
aqueous part for accommodation of hydrophilic molecules. Rather unexpected results were the size 
distributions of plain liposomes. However, similar findings that polymer-coated liposomes were 
smaller than non-coated liposomes were reported earlier [26,27]. The reason behind this observation 
could be that chitosan is known to form a cage-like steric barrier that protects liposomes from 
aggregation, whereas in the case of non-coated liposomes the agglomeration can occur [26]. 
Table 1. Size distributions of liposomes. All values represent the mean size ± SD, and are 
volume-weighted (%) bimodal distribution (n = 3). 
Type of Liposomes 
Peak 1 * Peak 2 * 
PI 
Size (nm) % Size (nm) % 
FITC-dextran 4      
Chitosan-containing 76 ± 40 20 ± 7 287 ± 48 79 ± 9 0.30 ± 0.01 
Chitosan-coated 48 ± 25 69 ± 3 197 ± 27 21 ± 3 0.35 ± 0.15 
Plain 56 ± 20 16 ± 13 337 ± 53 85 ± 13 0.36 ± 0.08 
FITC-dextran 20      
Chitosan-containing 50 ± 19 29 ± 7 257 ± 42 64 ± 8 0.33 ± 0.01 
Chitosan-coated 27 ± 4 26 ± 9 99 ± 18 74 ± 9 0.34 ± 0.01 
Plain 51 ± 3 39 ± 2 219 ± 3 54 ± 24 0.37 ± 0.05 
* The values are shown as a Nicomp distribution, which gave the best fit for the measured data (Fit error 
<1.5; residual error <10). 
The zeta potential of the plain liposomes, regardless of the type of the entrapped FITC-dextran,  
was close to neutral (0.93 mV), which is expected since the lipid used to form vesicles is neutral.  
The chitosan containing formulations, chitosan-containing and chitosan-coated liposomes, exhibited  
a positive zeta potentials (2.45 and 6.73 mV, respectively) reflecting the positive charge of the  
surface-available chitosan. 
2.2. Surface-Available Chitosan 
Although the zeta potentials indicated the presence of chitosan on the liposomal surface for both the 
chitosan-containing and chitosan-coated liposomes, we wanted to confirm that chitosan is indeed 
available to interact with mucin and thus ensure the system’s bioadhesiveness. In the case of the 
chitosan-containing liposomes, where chitosan was present during the formation of the liposomes, it is 
expected that a proportion of the polymer is lodged inside the lamellar structure of the liposomes. 
Therefore, to prove this hypothesis, the availability of chitosan on the surfaces of all liposomes was 
evaluated. As can be seen in Figure 2, the plain liposomes did not exhibit any (or in a negligent 
amount) surface-available chitosan. The small percentage detected can be due to a limitation of the 
test. The chitosan-containing and chitosan-coated liposomes exhibited a high degree of  
surface-available chitosan; the chitosan-coated vesicles contained significantly (p < 0.01) more 
chitosan on their surface (80%) as compared to the chitosan-containing liposomes (approx. 65%). 
Considering that for the chitosan-coated liposomes all, or most of the chitosan, should be  
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surface-available, this finding was as expected. The fact that about 35% of chitosan was not  
surface-available in the chitosan-containing liposomes indicated that parts of chitosan are indeed 
embedded within this type of liposomes, and proved our initial hypothesis. These findings are also in 
agreement with the zeta potentials measured on liposomal surfaces where the chitosan-coated 
liposomes exhibited higher zeta potential. 
 
Figure 2. Percentage of surface-available chitosan determined in chitosan-containing, 
chitosan-coated liposomes, and plain liposomes. All values represent the mean ± SD  
(n = 3). 
2.3. Mucin-Binding Properties of Liposomes 
After confirming that there are high amounts of surface-oriented chitosan available for possible 
interaction with mucin, both on the surface of the chitosan-containing and chitosan-coated liposomes, 
an in vitro mucin test was applied to confirm the system’s adhesiveness. The binding efficiency of the 
liposomes to the model porcine mucin (PM) was used to demonstrate the mucin-binding capability of 
the formulations and to estimate the mucoadhesive behavior. The chitosan-coated liposomes exhibited 
the highest PM binding efficiency, closely followed by the chitosan-containing liposomes, while the 
plain liposomes, as expected, exhibiting lower mucoadhesiveness (Figure 3). These findings were in 
direct agreement with the chitosan surface availability data (Figure 2) where the chitosan-coated 
liposomes were shown to have more available chitosan on the surface. However, even though the 
chitosan-containing and chitosan-coated liposomal formulations were significantly different (p < 0.05) 
regarding the mucin-binding capacity, this was less pronounced than the difference in the amount of 
surface available chitosan. The plain liposomes exhibited the PM binding efficiency of about 50%, 
which is significantly less (p < 0.001) than the other two liposomal formulations. One can argue that 
plain liposomes should have negligible mucin-binding capacity; however due to the ultracentrifugation 
applied to separate liposomes from bound mucin, it is possible that some plain liposomes interacted 
physically with the mucin without the actual electrostatic interactions that were targeted in the test. It is 
also possible that there is a hydrophobic interaction between the liposomes and mucin that leads to the 
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findings in Figure 3. Our findings are also comparable to the results reported earlier for the sonicated 
plain liposomes [27]. 
 
Figure 3. Binding efficacy of the liposomes to porcine mucin. All values represent the  
mean ± SD (n = 3). 
2.4. In Vitro Release of FITC-Dextrans from Liposomes 
Cumulative release of FITC-dextran 4 and FITC-dextran 20 from all three liposomal formulations is 
shown in Figures 4 and 5, respectively. All three types of delivery systems released FITC-dextran 4 in 
a sustained manner as compared to the FITC-dextran 4 solution (Figure 4). The chitosan-containing 
liposomes were found to sustain the initial release to a greater extent than the chitosan-coated 
liposomes, however after 2 h the release of FITC-dextran 4 was slower from the chitosan-coated 
compared to chitosan-containing liposomes although not on significant level. The release of the high 
molecular weight FITC-dextran 20 (Figure 5) was found to be faster than the release of low molecular  
FITC-dextran 4. Again the control (FITC-dextran 20 solution) exhibited the highest cumulative 
release; however in this case the chitosan-containing liposomes sustained the release of FITC-dextran 
20 to the greatest extent among the tested formulations. Interestingly, the chitosan-coated liposomes 
released more FITC-dextran 20 than the plain liposomes (Figure 5), which is exactly the opposite 
behavior as found for the low molecular weight FITC-dextran 4. Another interesting observation was 
the fast initial release of FITC-dextran from all liposomal formulations. It seems that the  
chitosan-coated liposomes provided an initial burst release of the high molecular weight fluorescent 
marker. One possible explanation can be that the rather large molecule of FITC-dextran 20  
(20,000 Da) was not only entrapped but also embedded between the vesicle bilayers close to the outer 
bilayer and was released by a rapid diffusion at the start of the release study. In addition, the smaller 
liposomal size, and thus the larger total surface area of liposomes containing FITC-dextran 20 could 
facilitate its faster release as compared to the release of FITC-dextran 4. 
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Figure 4. Cumulative release of FITC-dextran 4 from chitosan-containing liposomes, 
chitosan-coated liposomes, and plain liposomes. All values represent the mean ± SD  
(n = 3). 
 
Figure 5. Cumulative release of FITC-dextran 20 from chitosan-containing liposomes, 
chitosan-coated liposomes, and plain liposomes. All values represent the mean ± SD  
(n = 3). 
Based on the surface availability of chitosan on the chitosan-containing liposomes, and the ability to 
bind to mucin, this type of liposomes offers the potential to adhere to the vaginal mucosa and reside at 
the vaginal site for a prolonged period of time to ensure sufficiently high amounts of the drug at the 
site of action. The entrapment of large molecular weight model substances in the chitosan-containing 
liposomes was superior to entrapment of the same substances in the chitosan-coated liposomes. 
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Moreover, the release of incorporated model substances of higher molecular weights (4000 and  
20,000 Da) indicates that the chitosan-containing liposomes will release the incorporated material  
(e.g., drug) in a sustained manner. The fate of intravaginally administered drugs can be seen as a  
multi-compartment interactive event where the effects of the delivery system, the amount and viscosity 
of vaginal fluid, the presence of semen, the epithelium conditions and disease state need to be 
considered when optimizing the formulation [28]. Additional advantage of chitosan is its non-toxicity, 
as it is expected that chitosan-based delivery systems will not cause vaginal irritation. Very recently, 
the indications that chitosan can disrupt the bacterial biofilms in bacterial vaginosis have been reported, 
which would strengthen the potentials of chitosan as vaginal mucoadhesive delivery system [29]. 
3. Experimental Section 
3.1. Materials 
Soy phosphatidylcholine (Lipoid S100, Lipoid GmbH, Ludwigshafen, Germany) was a generous 
gift by Lipoid GmbH. Chitosan (60,000 Da; 77% degree of deacetylation (DD)), two types of 
fluorescein isothiocyanate dextran (FITC-dextran 4 and FITC-dextran 20 corresponding Mw 4000 and 
20,000, respectively), mucin from porcine stomach type II, Triton X, methanol and n-propanol were all 
products of Sigma Aldrich Inc. (Steinheim, Germany). Cibacron Brilliant Red 3B-A was purchased 
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Sepharose CL-4B gel was ordered from 
Pharmacia Bioteck AB (Uppsala, Sweden). All other chemicals used in the experiments were of 
analytical grade. 
3.2. Preparation of Vesicles 
3.2.1. Preparation of Chitosan-Containing Liposomes 
Chitosan-containing liposomes were prepared by the one-pot preparation method previously 
developed in our research group [21]. Briefly, Lipoid S100 (SPC, 200 mg) was dissolved in an 
adequate amount of methanol. The solvent was evaporated using a rotoevaporator system (Büchi 
rotavapor R-124, with vacuum controller B-721, Büchi vac V-500, Büchi Labortechnik, Flawil, 
Switzerland) under a vacuum at 45 °C. The resulting film was redispersed with 100 μL of n-propanol 
by help of a micro syringe pipette (Hamilton, Bonaduz, Switzerland). The dispersion was  
needle-injected into 2 mL of aqueous media containing 0.17% (w/w) chitosan in 0.1% (v/v) acetic acid 
and either FITC-dextran 4 or FITC-dextran 20 (42.0 mg) and stirred for 2 h at room temperature  
(23 °C). The dispersion was left in a refrigerator overnight prior to vesicle size reduction  
and characterization. 
3.2.2. Plain Liposomes 
Plain, non-mucoadhesive liposomes, were prepared under the same conditions using the same lipid 
composition to prepare the film, which was subsequently redispersed and injected into aqueous 
solution of either FITC-dextran 4 or FITC-dextran 20. The dispersion was left in a refrigerator 
overnight prior to vesicle size reduction and characterization. 
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3.2.3. Vesicle Size Reduction 
The chitosan-containing and plain (non-mucoadhesive) liposomes were reduced to a smaller size by 
sonication using a Sonics High Ultrasonic Processor (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany). Prior to sonication, the samples were diluted to a suitable volume (5 mL) with distilled 
water and sonicated for 45 s using an ice bath to prevent heating of the samples. 
3.2.4. Chitosan-Coated Liposomes 
Coating of sonicated plain FITC-dextran containing liposomes was performed by a previously 
reported method [17]. In brief, the chitosan solution (0.1% w/v) in glacial acetic acid (0.1% v/v) was 
added drop-wise to an equal volume of liposomes under the controlled magnetic stirring at room 
temperature for 1 h. Upon completion of stirring, the dispersion was left in a refrigerator overnight. 
3.3. Entrapment Efficiency 
In order to remove the unentrapped FITC-dextrans from liposomes two different separation 
methods were used, depending of the molecular weight of the model substance. For the liposomes 
containing FITC-dextran 4, dialysis in a dialysis membrane (Mw cut off: 12–14,000 Daltons; Medicell 
International Ltd., London, UK) against distilled water was applied for 24 h at room temperature. For 
liposomes containing FITC-dextran 20, a column separation on a Sepharose CL-4B gel was used. 
The entrapment efficiency of the liposomal formulations was determined by fluorescence 
measurements using a Polarstar flourimeter (Fluostar, BMG Technologies, Offenburg, Germany) on 
excitation and emission wavelengths of 485 and 520 nm, respectively. To dissolve lipid, liposomal 
samples were pretreated by addition of 10% (v/v) of Triton X in a volume ratio of 1:1. Standard curves 
for both FITC-dextrans in water and FITC-dextrans in aqueous Triton X solutions were prepared and 
used for the fluorescence determination. 
3.4. Particle Size Analysis 
The size distributions were measured by photon correlation spectroscopy using a Submicron  
Particle-sizer (Model 360, Nicomp, Santa Barbara, CA, USA). To avoid possible interference caused 
by dust particles, test tubes were pre-rinsed with distilled water and bath-sonicated for 10 min. In 
addition, all sample preparations were performed in a laminar airflow bench. The liposomal samples 
were diluted with filtered (0.2 μm Milipore filters) distilled water to provide appropriate count 
intensity (approx. 250–350 kHz) and measured in three parallels (run time 10 min at 23 °C). Both 
Gausssian and Nicomp algorithms were fitted to the experimental data to find the distribution that best 
describes the particle population [30]. As the fit error was found to be smaller than 1.5, and the 
residual error was smaller than 10, Nicomp distribution was selected. The volume-weighted 
distribution was used to determine the mean diameter and PI of all samples. 
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3.5. Zeta Potential Determination 
The zeta potential of all liposomes was measured on a Malvern Zetasizer Nano ZS  
(Malvern Instruments Ltd, Oxford, UK). The instrument was calibrated throughout the measurements 
using the Malvern zeta potential transfer standard (−50 ± 5 mV). The samples were diluted in  
filtered water until an appropriate count rate was achieved and measured in a measuring cell.  
All measurements were performed at 23 °C and the results represent an average of at least three 
independent measurements [16]. 
3.6. Determination of Surface-Available Chitosan 
To determine the surface-available chitosan the colorimetric method originally reported by 
Muzzarelli [31] was applied. Glycine buffer (pH 3.2) was prepared by dissolving 1.87 g of glycine and 
1.46 g of NaCl in 250 mL of distilled water; an aliquot of 81 mL was further diluted with 0.1 M HCl to 
a final volume of 100 mL. Cibacron Brilliant Red 3B-A (150 mg) was dissolved in 100 mL of  
distilled water. The dye solution (5 mL) was further diluted to 100 mL with the glycine buffer.  
Liposomal suspensions were diluted with distilled water to desirable concentration (1:2, v/v) before  
3 mL of the final dye solution was added. UV absorbance was measured photometrically at 575 nm  
(Agilent Technologies, Santa Clara, CA, USA). The surface-available chitosan was calculated using 
the following equation: 
 
where Cs is the concentration of surface-available chitosan in the sample and Cc is the concentration 
of chitosan used to prepare the liposomal formulations. 
A standard curve was made by suspending chitosan powder (0.5 g) in 50 mL of distilled water.  
After 30 min at room temperature, 2.0 mL of glacial acetic acid (99.8% w/w) was added.  
An additional 50 mL of distilled water was added to acidic chitosan solution, before the final dilution 
with distilled water provided a final concentration of 0.5 g/L. Standard solutions were made by diluting 
the chitosan solution with glycine buffer to desired concentrations. 
3.7. Mucin-Binding Test as Indicator of Mucoadhesiveness 
The mucoadhesive properties were determined by the method developed by Pawar et al. [32] and 
modified in our group [27]. The porcine mucin (PM; 400 μg/mL) was hydrated in the phosphate buffer 
(0.05 M, pH 7.4), the suspension mixed with the vesicle suspension (1:1, v/v) and the mixture 
incubated at room temperature (23 °C) for 2 h prior to centrifugation for 60 min at 216,000× g and  
10 °C (Optima LE-80; Beckman Instruments, Palo Alto, CA, USA). Absorbance of the remaining free PM 
in the supernatants was measured by UV spectrophotometry (Microtitre plate reader; Spectra Max 190 
Microplate, Spectrophotometer Molecular Devices, Sunnyvale, CA, USA) at 251 nm. The 
mucoadhesiveness was expressed as PM binding efficiency calculated by the following equation: 
𝑃𝑀 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 𝑒𝑓𝑓. =  (
𝐶0−𝐶𝑆
𝐶0
) × 100 
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where C0 is the initial concentration of PM used for incubation (400 μg/mL) and CS is the measured 
concentration of free PM in the supernatant after removal of the liposome-bound PM. The standard 
curve was determined from the standard PM solutions in the phosphate buffer made by diluting the PM 
stock solution to 40, 80, 120, 160, 200, 240, 280, and 320 μg/mL, respectively. 
3.8. In Vitro Release Studies 
Release studies were performed using the Franz diffusion cells (PermeGear, Hellertown, PA, USA) 
with the heating circulator (Julabo Labortechnik F12-ED, Seelback, Germany) maintaining the 
temperature at 37 °C. The cells with 12 mL volume acceptor chambers and a diffusion area of 1.77 cm2 
were used in in vitro studies based on the method by Hurler et al. [33] Polyamide membranes  
(0.2 μm pore size, Sartorius polyamide membrane; Sartorius AG, Gröttingen, Germany) were used.  
The formulations were added to the donor compartment in a volume of 600 μL. The acceptor chambers 
were filled with distilled water, and kept at 37 °C. Samples (500 μL) from the acceptor medium were 
taken at 30, 60, 120, 240, 360 and 480 min, and replaced with the fresh medium. Both the sampling 
port and the donor chamber were covered with quadruple layers of parafilm to prevent evaporation. 
Quantification of released fluorescent markers was determined based on the flourimetric measurements 
at excitation and emission wavelengths of 485 and 520 nm, respectively. All experiments were carried 
out in triplicate. 
3.9. Statistical Evaluation 
The student’s t-test was used for comparison of two means. A significance level of p < 0.05 was 
considered to be appropriate. 
4. Conclusions 
The mucoadhesive nanosize delivery systems, the chitosan-containing liposomes, were shown to 
entrap/incorporate higher amounts of the fluorescent model substances of different molecular weight 
(4000 and 20,000 Da) as compared to conventional plain and chitosan-coated liposomes. The higher 
entrapment can be explained by the embedding of chitosan also within the lamellar structure of the 
liposomes and not only on the surface as proven in the surface-availability tests. The chitosan-containing 
liposomes were also able to ensure sustained release of entrapped material. The ability of  
surface-available chitosan to interact with mucus was confirmed indicating system’s potential to 
prolong the residence time at the vaginal site. 
Acknowledgments 
The authors are grateful to Lipoid GmbH, Ludwigshafen, Germany for a continuous support in 
supplying the lipids. 
  
Mar. Drugs 2015, 13 234 
 
 
Author Contributions 
T.A., G.E.F., I.T., S.M. and N.S-B. designed and planned the experiments. T.A. and S.B. conducted 
the experiments. All authors contributed to the manuscript preparation. N. S-B. is a senior author and 
project leader. 
Conflict of Interests 
The authors declare no conflict of interests. 
References 
1. Prashant, K.V.H.; Tharanathan, R.N. Chitin/chitosan: Modifications and their unlimited 
application potential- an overview. Trends Food Sci. Technol. 2007, 18, 117–131. 
2. Pal, K.; Behera, B.; Roy, S.; Ray, S.S.; Thakur, G. Chitosan based delivery systems on a length 
scale: Nano to macro. Soft Mater. 2013, 11, 125–142. 
3. Bernkop-Schnuerch, A.; Duennhaupt, S. Chitosan-based drug delivery systems. Eur. J.  
Pharm. Biopharm. 2012, 81, 463–469. 
4. Uchgebu, I.F.; Carlos, M.; McKay, C.; Hou, X.; Schaetzlein, A.G. Chitosan amphiphiles provide 
new drug delivery opportunities. Polym. Int. 2014, 63, 1145–1153. 
5. Dash, M.; Chiellini, F.; Ottenbrite, R.M.; Chiellini, E. Chitosan-A versatile semisynthetic polymer 
in biomedical applications. Prog. Polym. Sci. 2011, 36, 981–1014. 
6. Kean, T.; Thanou, M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug  
Deliv. Rev. 2010, 62, 3–11. 
7. Kim, I.-Y.; Seo, S.-J.; Moon, H-S.; Yoo, M.-K.; Park, I.-Y.; Kim, B.-C.; Cho, C.-S. Chitosan and 
its derivatives for tissue engineering applications. Biotechnol. Adv. 2008, 26, 1–21. 
8. Bhattarai, N.; Gunn, J.; Zhang, M. Chitosan-based hydrogels for controlled, localized drug 
delivery. Adv. Drug Deliv. Rev. 2010, 62, 83–99. 
9. Jayakumar, R.; Menon, D.; Manzoor, K.; Nair, S.V.; Tamura, H. Biomedical applications of chitin 
and chitosan based nanomaterials—A short review. Carbohyd. Polym. 2010, 82, 227–232. 
10. Singla, A.K.; Chawla, M. Chitosan: Some pharmaceutical and biological aspects—An update.  
J. Pharm. Pharmacol. 2001, 53, 1047–1067. 
11. Perioli, L.; Ambrogi, V.; Venezia, L.; Pagano, C.; Ricci, M.; Rossi, C. Chitosan and modified 
chitosan as agents to improve performances of mucoadhesive vaginal gels. Colloids Surf.  
B Biointerfaces 2008, 66, 141–145. 
12. Li, N.; Zhuang, C.; Wang, M.; Sun, X.; Nie, S.; Pan, W. Liposomes coated with low molecular 
weight chitosan and its potential use in ocular drug delivery. Int. J. Pharm. 2009, 379, 131–139. 
13. Zaru, M.; Manca, M.-L.; Fadda, A.M.; Antimisiaris, S.G. Chitosan-coated liposomes for delivery 
to lungs by nebulization. Colloids Surf. B Biointerfaces 2009, 71, 88–95. 
14. Calderon, L.; Harris, R.; Cordoba-Diaz, M.; Elorza, M.; Elorza, B.; Lenoir, J.; Andriaens, E.; 
Remon, J.P.; Heras, A.; Cordoba-Diaz, D. Nano and microparticulate chitosan-based systems for 
antiviral topical delivery. Eur. J. Pharm. Sci. 2013, 48, 216–222. 
Mar. Drugs 2015, 13 235 
 
 
15. Casettari, L.; Illum, L. Chitosan in nasal delivery systems for therapeutic drugs. J. Control. 
Release 2014, 190, 189–200. 
16. Vanić, Ž.; Škalko-Basnet, N. Mucosal nanosystems for improved topical drug delivery: Vaginal 
route of administration. J. Drug. Del. Sci. Technol. 2014, 24, 435–444. 
17. Jøraholmen, M.W.; Vanić, Ž.; Tho, I.; Škalko-Basnet, N. Chitosan-coated liposomes for topical 
vaginal therapy: Assuring localized drug effect. Int. J. Pharm. 2014, 472, 94–101. 
18. Berginc, K.; Suljaković, S.; Škalko-Basnet, N.; Kristl, A. Mucoadhesive liposomes as new 
formulations for vaginal delivery of curcumin. Eur. J. Pharm. Biopharm. 2014, 87, 40–46. 
19. Valenta, C. The use of mucoadhesive polymers in vaginal delivery. Adv. Drug Delivery Rev. 
2005, 57, 1692–1712. 
20. Vanić, Ž.; Škalko-Basnet, N. Nanopharmaceuticals for improved topical vaginal therapy: Can 
they deliver? Eur. J. Pharm. Sci. 2013, 50, 29–41. 
21. Andersen, T.; Vanić, Ž.; Flaten, G.E.; Mattsson, S.; Tho, I.; Škalko-Basnet, N. Pectosomes and 
chitosomes as delivery systems for metronidazole: The one-pot preparation method. 
Pharmaceutics 2013, 5, 445–456. 
22. Vanić, Ž.; Planinšek, O.; Škalko-Basnet, N.; Tho, I. Tablets of pre-liposomes govern in situ 
formation of liposomes: Concept and potential of the novel drug delivery system. Eur. J.  
Pharm. Biopharm. 2014, 88, 443–454. 
23. Hainer, B.L.; Gibson, M.V. Vaginitis: Diagnosis and treatment. Am. Fam. Physician 2011, 83,  
807–825. 
24. Andrews, G.P.; Laverty, T.P.; Jones, D.S. Mucoadhesive polymeric platforms for controlled drug 
delivery. Eur. J. Pharm. Biopharm. 2009; 71, 505–518. 
25. Das Neves, J.; Bahia, M.F.; Amiji, M.M; Sarmento, B. Mucoadhesive nanomedicines: 
Characterization and modulation of mucoadhesion at the nanoscale. Expert Opin. Drug Deliv. 
2011, 8, 1085–1104. 
26. Tan, H.W.; Mishran, M. Characterization of fatty acid liposome coated with low molecular-weight 
chitosan. J. Liposome Res. 2012; 22, 329–335. 
27. Naderkhani, E.; Erber, A.; Škalko-Basnet, N.; Flaten, G.E. Improved permeability of acyclovir: 
Optimization of mucoadhesive liposomes using the Phospholipid Vesicle-Based Permeation 
Assay. J. Pharm. Sci. 2014, 103, 661–668. 
28. Katz, D.F.; Gao, Y.; Kang, M. Using modeling to help understand vaginal microbicide 
functionality and create better products. Drug Deliv. Transl. Res. 2011, 1, 256–276. 
29. Kandimalla, K.K.; Borden, E.; Omtri, R.S., Boyapati, S.P.; Smith, M.; Lebby, K.; Mulpuru, M.; 
Gadde, M. Ability of chitosan gels to disrupt bacterial biofilms and their applications in the 
treatment of bacterial vaginosis. J. Pharm. Sci. 2013, 102, 2096–2101. 
30. Di Cagno, M.; Styskala, J.; Hlavac, J.; Brandl, M.; Bauer-Brandl, A.; Škalko-Basnet, N.  
Liposomal solubilization of new 3-hydroxy-quinolinone derivatives with promising anticancer 
activity: A screening method to identify maximum incorporation capacity. J. Liposome Res. 2011, 
21, 272–278. 
  
Mar. Drugs 2015, 13 236 
 
 
31. Muzzarelli, R.A.A. Colorimetric determination of chitosan. Anal. Biochem. 1998, 260, 255–257. 
32. Pawar, H.; Douroumis, D.; Boateng, J.S. Preparation and optimization of PMAA-chitosan-PEG 
nanoparticles for oral drug delivery. Colloids Surf. B Biointerfaces 2012, 90, 102–108. 
33. Hurler, J.; Berg, O.A.; Skar, M.; Conradi, A.H.; Johnsen, P.J.; Škalko-Basnet, N. Improved  
burns therapy: Liposomes-in-hydrogel delivery system for mupirocin. J. Pharm. Sci. 2012, 101,  
3906–3915. 
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
